Roche Holding has one of the most promising treatments for Alzheimer’s in clinical trials. The drug is several years away ...

Since the 2023 financing round, Flare’s lead program FX-909 has moved into a phase 1 clinical trial for patients with ...

Alongside opening the new offices, Roche Diagnostics' capabilities in China have been further recognised as it has been ...

New data highlight the potential of the Roche Elecsys® Amyloid Plasma Panel and Elecsys ptau181 for ruling out Alzheimer’s ...

Carolyn Kay, medical affairs lead at Roche Diagnostics, said it’s “exciting” that these tests are now available in the U.S., ...

Cepheid and Roche Diagnostics Tests Provide Rapid and Decentralized Detection Options as Mpox Cases Continue to Rise ...

Roche confirmed its profit outlook for the year after its eye drug Vabysmo, multiple-sclerosis treatment Ocrevus and ...

Roche Holding AG (RHHVF) Company Description: Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The ...

Roche is aligning with Flare Therapeutics to work on small molecules for cancer by going after transcription factor targets, ...

On November 8, 2024, Roche Diagnostics enhanced the company's long term commitment to China's local healthcare industry, to ultimately benefit patients in China and beyond, with the opening of its ...